{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T21:22:02Z","timestamp":1792531322105,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T00:00:00Z","timestamp":1634428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T00:00:00Z","timestamp":1634428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2022,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Renal denervation is a potential alternative to antihypertensive drug therapy. However, data on patient preference for this treatment option are limited and there are no data specifically from Asian patients. This study evaluated patient preference for renal denervation in patients with hypertension from Japan. Patients were a subset of those who participated in a March 2020 online electronic survey of patients with hypertension who had regularly visited medical institutions for treatment, were receiving antihypertensive drug therapy and had home blood pressure recordings available. The survey included a question about patient preference for treatment with renal denervation. A total of 2,392 patients were included (66% male, mean age 59.8\u2009\u00b1\u200911.6 years, mean duration of hypertension 11.4\u2009\u00b1\u20099.5 years). Preference for renal denervation was expressed by 755 patients (31.6%), and was higher in males than in females, in younger compared with older patients, in those with higher versus lower blood pressure, in patients who were less adherent versus more adherent to antihypertensive drug therapy, and in those who did rather than did not have antihypertensive drug-related side effects. Significant predictors of preference for renal denervation on logistic regression analysis were younger patient age, male sex, higher home or office systolic blood pressure, poor antihypertensive drug adherence, the presence of heart failure, and the presence of side effects during treatment with antihypertensive drugs. Overall, a relevant proportion of Japanese patients with hypertension expressed a preference for renal denervation. This should be taken into account when making shared decisions about antihypertensive drug therapy.<\/jats:p>","DOI":"10.1038\/s41440-021-00760-9","type":"journal-article","created":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T01:08:22Z","timestamp":1634432902000},"page":"232-240","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["A Japan nationwide web-based survey of patient preference for renal denervation for hypertension treatment"],"prefix":"10.1038","volume":"45","author":[{"given":"Kazuomi","family":"Kario","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Kagitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satsuki","family":"Hanamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kanegae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,17]]},"reference":[{"key":"760_CR1","unstructured":"World Health Organization. Hypertension fact sheet. Available at: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hypertension. Accessed 10 Aug 2021)."},{"key":"760_CR2","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1056\/NEJMsa0903829","volume":"361","author":"AV Chobanian","year":"2009","unstructured":"Chobanian AV, Shattuck Lecture. The hypertension paradox\u2013more uncontrolled disease despite improved therapy. N. Engl J Med. 2009;361:878\u201387.","journal-title":"N. Engl J Med"},{"key":"760_CR3","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019;42:1235\u2013481.","journal-title":"Hypertens Res"},{"key":"760_CR4","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1161\/CIRCRESAHA.119.314991","volume":"124","author":"N Hirawa","year":"2019","unstructured":"Hirawa N, Umemura S, Ito S. Viewpoint on Guidelines for Treatment of Hypertension in Japan. Circulation Res. 2019;124:981\u20133.","journal-title":"Circulation Res"},{"key":"760_CR5","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr., Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018;71:1269\u2013324.","journal-title":"Hypertension"},{"key":"760_CR6","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1161\/CIRCULATIONAHA.117.032851","volume":"137","author":"K Kario","year":"2018","unstructured":"Kario K. Global impact of 2017 American Heart Association\/American college of cardiology hypertension guidelines. Circulation. 2018;137:543\u20135.","journal-title":"Circulation"},{"key":"760_CR7","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","volume":"360","author":"S Lewington","year":"2002","unstructured":"Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903\u201313.","journal-title":"Lancet"},{"key":"760_CR8","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1001\/jamacardio.2017.1421","volume":"2","author":"JD Bundy","year":"2017","unstructured":"Bundy JD, Li C, Stuchlik P, Bu X, Kelly TN, Mills KT, et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA Cardiol. 2017;2:775\u201381.","journal-title":"JAMA Cardiol"},{"key":"760_CR9","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1152\/japplphysiol.00182.2010","volume":"109","author":"M Esler","year":"2010","unstructured":"Esler M, Lambert E, Schlaich M. Point: chronic activation of the sympathetic nervous system is the dominant contributor to systemic hypertension. J Appl Physiol (1985). 2010;109:1996\u20138. discussion 2016","journal-title":"J Appl Physiol (1985)"},{"key":"760_CR10","doi-asserted-by":"publisher","unstructured":"Katsurada K, Ogoyama Y, Imai Y, Patel KP, Kario K. New horizons in the treatment of hypertension: renal denervation based on experimental rationale. Hypertens Res. 2021 (e-pub ahead of print 2021\/09\/13, https:\/\/doi.org\/10.1038\/s41440-021-00746-7).","DOI":"10.1038\/s41440-021-00746-7"},{"key":"760_CR11","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1056\/NEJMoa1402670","volume":"370","author":"DL Bhatt","year":"2014","unstructured":"Bhatt DL, Kandzari DE, O\u2019Neill WW, D\u2019Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N. Engl J Med. 2014;370:1393\u2013401.","journal-title":"N. Engl J Med"},{"key":"760_CR12","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/S0140-6736(10)62039-9","volume":"376","author":"MD Esler","year":"2010","unstructured":"Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, B\u00f6hm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903\u20139.","journal-title":"Lancet"},{"key":"760_CR13","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/S0140-6736(09)60566-3","volume":"373","author":"H Krum","year":"2009","unstructured":"Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275\u201381.","journal-title":"Lancet"},{"key":"760_CR14","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/S0140-6736(21)00788-1","volume":"397","author":"M Azizi","year":"2021","unstructured":"Azizi M, Sanghvi K, Saxena M, Gosse P, Reilly JP, Levy T, et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial. Lancet. 2021;397:2476\u201386.","journal-title":"Lancet"},{"key":"760_CR15","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1016\/S0140-6736(18)31082-1","volume":"391","author":"M Azizi","year":"2018","unstructured":"Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Davies J, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet. 2018;391:2335\u201345.","journal-title":"Lancet"},{"key":"760_CR16","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1161\/CIRCULATIONAHA.119.040451","volume":"139","author":"M Azizi","year":"2019","unstructured":"Azizi M, Schmieder RE, Mahfoud F, Weber MA, Daemen J, Lobo MD, et al. Six-month results of treatment-blinded medication titration for hypertension control after randomization to endovascular ultrasound renal denervation or a sham procedure in the RADIANCE-HTN SOLO trial. Circulation. 2019;139:2542\u201353.","journal-title":"Circulation"},{"key":"760_CR17","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1016\/S0140-6736(20)30554-7","volume":"395","author":"M B\u00f6hm","year":"2020","unstructured":"B\u00f6hm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmieder RE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. 2020;395:1444\u201351.","journal-title":"Lancet"},{"key":"760_CR18","doi-asserted-by":"publisher","first-page":"2346","DOI":"10.1016\/S0140-6736(18)30951-6","volume":"391","author":"DE Kandzari","year":"2018","unstructured":"Kandzari DE, B\u00f6hm M, Mahfoud F, Townsend RR, Weber MA, Pocock S, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391:2346\u201355.","journal-title":"Lancet"},{"key":"760_CR19","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1016\/S0140-6736(17)32281-X","volume":"390","author":"RR Townsend","year":"2017","unstructured":"Townsend RR, Mahfoud F, Kandzari DE, Kario K, Pocock S, Weber MA, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390:2160\u201370.","journal-title":"Lancet"},{"key":"760_CR20","doi-asserted-by":"crossref","unstructured":"Kim BK, Kim HS, Park SJ, Park CG, Seung KB, Gwon HC, et al. Long-term outcomes after renal denervation in an Asian population: results from the Global SYMPLICITY Registry in South Korea (GSR Korea). Hypertens Res. 2021;44:1099\u2013104.","DOI":"10.1038\/s41440-021-00683-5"},{"key":"760_CR21","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1253\/circj.CJ-15-0150","volume":"79","author":"K Kario","year":"2015","unstructured":"Kario K, Ogawa H, Okumura K, Okura T, Saito S, Ueno T, et al. SYMPLICITY HTN-Japan - first randomized controlled trial of catheter-based renal denervation in Asian patients. Circ J. 2015;79:1222\u20139.","journal-title":"Circ J"},{"key":"760_CR22","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1161\/HYPERTENSIONAHA.117.10238","volume":"71","author":"K Kario","year":"2018","unstructured":"Kario K, Chen CH, Park S, Park CG, Hoshide S, Cheng HM, et al. Consensus document on improving hypertension management in Asian patients, taking into account Asian characteristics. Hypertension. 2018;71:375\u201382.","journal-title":"Hypertension"},{"key":"760_CR23","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1056\/NEJM198903023200905","volume":"320","author":"HH Zhou","year":"1989","unstructured":"Zhou HH, Koshakji RP, Silberstein DJ, Wilkinson GR, Wood AJ. Racial differences in drug response. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. N. Engl J Med. 1989;320:565\u201370.","journal-title":"N. Engl J Med"},{"key":"760_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2169\/internalmedicine.9059-17","volume":"57","author":"K Okamura","year":"2018","unstructured":"Okamura K, Shirai K, Okuda T, Urata H. The prevalence of Japanese outpatients with hypertension who meet the definition of treatment resistant hypertension and are eligible for enrolment in clinical trials of endovascular ultrasound renal denervation. Intern Med. 2018;57:1\u201312.","journal-title":"Intern Med"},{"key":"760_CR25","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1007\/s00392-019-01468-0","volume":"108","author":"RE Schmieder","year":"2019","unstructured":"Schmieder RE, H\u00f6gerl K, Jung S, Bramlage P, Veelken R, Ott C. Patient preference for therapies in hypertension: a cross-sectional survey of German patients. Clin Res Cardiol. 2019;108:1331\u201342.","journal-title":"Clin Res Cardiol"},{"key":"760_CR26","doi-asserted-by":"publisher","first-page":"3586","DOI":"10.1016\/S0735-1097(20)34213-3","volume":"75","author":"S-I Lin","year":"2020","unstructured":"Lin S-I, Li SH-W, Lan W-R, Liao F-C, Tsai CT, Lee Y-H. Understanding the patient preference for catheter-based hypertension therapy: a pilot study for physician awareness of patients\u2019 behaviour in Taiwan. J Am Coll Cardiol. 2020;75:3586.","journal-title":"J Am Coll Cardiol"},{"key":"760_CR27","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.1016\/S0735-1097(20)34134-6","volume":"75","author":"S-I Lin","year":"2020","unstructured":"Lin S-I, Li SH-W, Lan W-R, Liao F-C, Tsai CT, Lee Y-H. Subtypes of patient preference for catheter-based hypertension hterapy: a piloto study based on Taiwan consensus on renal denervation (RDNI2). J Am Coll Cardiol. 2020;75:3507.","journal-title":"J Am Coll Cardiol"},{"key":"760_CR28","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/HJH.0000000000002592","volume":"39","author":"RE Schmieder","year":"2021","unstructured":"Schmieder RE, Kandzari DE, Wang TD, Lee YH, Lazarus G, Pathak A. Differences in patient and physician perspectives on pharmaceutical therapy and renal denervation for the management of hypertension. J Hypertens. 2021;39:162\u20138.","journal-title":"J Hypertens"},{"key":"760_CR29","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1161\/HYPERTENSIONAHA.116.07201","volume":"68","author":"S Hoshide","year":"2016","unstructured":"Hoshide S, Yano Y, Haimoto H, Yamagiwa K, Uchiba K, Nagasaka S, et al. Morning and evening home blood pressure and risks of incident stroke and coronary artery disease in the Japanese general practice population: the Japan morning surge-home blood pressure study. Hypertension. 2016;68:54\u201361.","journal-title":"Hypertension"},{"key":"760_CR30","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1161\/HYPERTENSIONAHA.114.04262","volume":"64","author":"K Kario","year":"2014","unstructured":"Kario K, Saito I, Kushiro T, Teramukai S, Ishikawa Y, Mori Y, et al. Home blood pressure and cardiovascular outcomes in patients during antihypertensive therapy: primary results of HONEST, a large-scale prospective, real-world observational study. Hypertension. 2014;64:989\u201396.","journal-title":"Hypertension"},{"key":"760_CR31","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/s41440-018-0050-4","volume":"41","author":"D Watabe","year":"2018","unstructured":"Watabe D, Asayama K, Hanazawa T, Hosaka M, Satoh M, Yasui D, et al. Predictive power of home blood pressure indices at baseline and during follow-up in hypertensive patients: HOMED-BP study. Hypertens Res. 2018;41:622\u20138.","journal-title":"Hypertens Res"},{"key":"760_CR32","doi-asserted-by":"publisher","first-page":"E153","DOI":"10.1002\/ccd.26475","volume":"89","author":"W Chen","year":"2017","unstructured":"Chen W, Ling Z, Xu Y, Liu Z, Su L, Du H, et al. Preliminary effects of renal denervation with saline irrigated catheter on cardiac systolic function in patients with heart failure: a prospective, randomized, controlled, pilot study. Catheter Cardiovasc Inter. 2017;89:E153\u2013e161.","journal-title":"Catheter Cardiovasc Inter"},{"key":"760_CR33","first-page":"9779","volume":"8","author":"Q Dai","year":"2015","unstructured":"Dai Q, Lu J, Wang B, Ma G. Effect of percutaneous renal sympathetic nerve radiofrequency ablation in patients with severe heart failure. Int J Clin Exp Med. 2015;8:9779\u201385.","journal-title":"Int J Clin Exp Med"},{"key":"760_CR34","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.ijcard.2012.09.019","volume":"162","author":"JE Davies","year":"2013","unstructured":"Davies JE, Manisty CH, Petraco R, Barron AJ, Unsworth B, Mayet J, et al. First-in-man safety evaluation of renal denervation for chronic systolic heart failure: primary outcome from REACH-Pilot study. Int J Cardiol. 2013;162:189\u201392.","journal-title":"Int J Cardiol"},{"key":"760_CR35","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s10741-017-9629-0","volume":"22","author":"H Fukuta","year":"2017","unstructured":"Fukuta H, Goto T, Wakami K, Ohte N. Effects of catheter-based renal denervation on heart failure with reduced ejection fraction: a systematic review and meta-analysis. Heart Fail Rev. 2017;22:657\u201364.","journal-title":"Heart Fail Rev"},{"key":"760_CR36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.repc.2016.07.007","volume":"36","author":"JQ Gao","year":"2017","unstructured":"Gao JQ, Xie Y, Yang W, Zheng JP, Liu ZJ. Effects of percutaneous renal sympathetic denervation on cardiac function and exercise tolerance in patients with chronic heart failure. Rev Port Cardiol. 2017;36:45\u201351.","journal-title":"Rev Port Cardiol"},{"key":"760_CR37","doi-asserted-by":"publisher","first-page":"e007421","DOI":"10.1161\/CIRCHEARTFAILURE.120.007421","volume":"14","author":"KP Kresoja","year":"2021","unstructured":"Kresoja KP, Rommel KP, Fengler K, von Roeder M, Besler C, L\u00fccke C, et al. Renal sympathetic denervation in patients with heart failure with preserved ejection fraction. Circ Heart Fail. 2021;14:e007421.","journal-title":"Circ Heart Fail"},{"key":"760_CR38","doi-asserted-by":"crossref","unstructured":"Schmieder RE, Mahfoud F, Mancia G, Azizi M, B\u00f6hm M, Dimitriadis K, et al. European Society of Hypertension position paper on renal denervation 2021. J Hypertens. 2021;39:1733\u201341.","DOI":"10.1097\/HJH.0000000000002933"},{"key":"760_CR39","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1161\/HYPERTENSIONAHA.119.13671","volume":"75","author":"K Kario","year":"2020","unstructured":"Kario K, Kim BK, Aoki J, Wong AY, Lee YH, Wongpraparut N, et al. Renal denervation in Asia: consensus statement of the asia renal denervation consortium. Hypertension 2020;75:590\u2013602.","journal-title":"Hypertension"},{"key":"760_CR40","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40292-020-00367-0","volume":"27","author":"RM Bruno","year":"2020","unstructured":"Bruno RM, Taddei S, Borghi C, Colivicchi F, Desideri G, Grassi G, et al. Italian Society of Arterial Hypertension (SIIA) position paper on the role of renal denervation in the management of the difficult-to-treat hypertensive patient. High Blood Press Cardiovasc Prev. 2020;27:109\u201317.","journal-title":"High Blood Press Cardiovasc Prev"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-021-00760-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-021-00760-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-021-00760-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T09:25:58Z","timestamp":1642497958000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-021-00760-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,17]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["760"],"URL":"https:\/\/doi.org\/10.1038\/s41440-021-00760-9","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,17]]},"assertion":[{"value":"27 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"K. Kario is contracted as an external medical adviser to Terumo Corporation. K. Kario has received speaker fees and works as a consultant to JIMRO Co.; research grant from Otsuka Medical Devices, Co., all outside the submitted work. H. Kagitani, S. Hayashi, S. Hanamura, and K. Ozawa are full-time employees of Terumo Corporation. H. Kanegae has no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}